uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia BGlobeNewsWire • 03/26/20
uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic PromotersGlobeNewsWire • 03/02/20
UniQure (QURE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/20/20
uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering ApproachGlobeNewsWire • 12/19/19
uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia BGlobeNewsWire • 12/08/19
uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene DezaparvovecGlobeNewsWire • 10/31/19
uniQure Announces Third Quarter 2019 Results and Highlights Recent Company ProgressGlobeNewsWire • 10/28/19
Gene Therapy Stocks Rocket On Rumor Roche Clinched Its Spark BuyoutInvestors Business Daily • 10/24/19